A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

NCT02831491 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped To pursue broader program objectives in oncology.

Conditions

Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: Ramucirumab
DRUG: Docetaxel

Sponsor

Eli Lilly and Company